Formulation of calcium phosphates/poly (d,l-lactide) blends containing gentamicin for bone implantation.
Implants to prevent or treat osteomyelitis are described, composed of phosphate/poly(d,l-lactide) blends containing the antibiotic gentamicin. Seven formulations of implants containing 3% gentamicin sulfate (GS) were prepared at 433 MPa and 693 MPa of compression pressure. The blends contained phosphates (25% hydroxyapatite (HAP), 75% tricalcium phosphate (TCP)) and 20% dl-PLA (weight average molecular weight, M(w): 30 kD). To prolong GS release, implants were coated with PLGA (M(w):100 kD) or dl-PLA (M(w): 200 kD). Various durations of GS release from these devices were demonstrated as feasible. Release times of more than 10 weeks were attained with implants coated with dl-PLA (M(w): 200 kD), greatly exceeding the performance of the commercial formulation.
Soriano
I
I
Departamento de Ingenieria Quimica y Tecnologia Farmaceutica. Facultad de Farmacia. Universidad de La Laguna, 38200, La Laguna, Spain.
Evora
C
C
D020341:Absorbable Implants; D002130:Calcium Phosphates / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D005839:Gentamicins / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006882:Hydroxyapatites / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010019:Osteomyelitis / Q000188:drug therapy; D010521:Periosteum / Q000378:metabolism; D011108:Polymers / Q000493:pharmacokinetics / Q000627:therapeutic use
D002130:Calcium Phosphates; D005839:Gentamicins; D006882:Hydroxyapatites; D011108:Polymers; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous